Furthermore, in a recent successful phase 2 clinical trial with the Aβ-antibody donanemab,44 Aβ-positive individuals with MCI or mild dementia were specifically selected based on intermediate levels of tau pathology on a PET scan. Here, MAPT is linked to dementia.